Present and future therapy options in IgA-nephropathy

Journal of Nephrology

Volumn 18, Issue 4, 2005, Pages 354-361

  Floege, Jürgen ^a   Eitner, Frank ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Glomerulonephritis; Hypertension; Immunosuppression; Proteinuria; Supportive therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BENAZEPRIL; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; CYTOKINE RECEPTOR ANTAGONIST; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOXYCYCLINE; ENALAPRIL; FISH OIL; MESALAZINE; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR D; PLATELET DERIVED GROWTH FACTOR RECEPTOR ANTAGONIST; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; UROKINASE; WARFARIN;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; GROWTH RETARDATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; NONHUMAN; PROTEINURIA; RENAL PROTECTION; REVIEW; SMOKING CESSATION; SYSTEMATIC REVIEW;

ANIMALS; DISEASE PROGRESSION; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSION;

EID: 28244465105     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Nolin L, Courteau M. Management of IgA nephropathy: Evidence-based recommendations. Kidney Int Suppl 1999; 70: S56-62.
2. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: Handle with caution. Nephrol Dial Transplant 2003; 18: 241-5.
3. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353: 883-7.
4. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F. Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-63.
5. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999; 10: 101-9.
6. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, Imai E, Hori M, Tsubakihara Y. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 2000; 35: 194-201.
7. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-8.
8. Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T, Masutani K, Kubo M, Fujimi S. Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41: 972-83.
9. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-9.
10. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24: 179-96.
11. Moriyama T, Honda K, Nitta K, Yumura W, Nihei H. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function. Clin Exp Nephrol 2004; 8: 237-42.
12. Sato M, Hotta O, Tomioka S, Horigome I, Chiba S, Miyazaki M, Noshiro H, Taguma Y. Cohort study of advanced IgA nephropathy: Efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clin Pract 2003; 93: c137-45.
13. Goumenos DS, Davlouros P, El Nahas AM, Ahuja M, Shortland JR, Vlachojannis JG, Brown CB. Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. Nephron Clin Pract 2003; 93: C58-68.
14. Roccatello D, Ferro M, Cesano G, Rossi D, Berutti S, Salomone M, Piccoli G, Sena LM. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000; 15: 833-5.
15. Harper L, Ferreira MA, Howie AJ, Savage CO, Richards NT, Michael J, Adu D. Treatment of vasculitic IgA nephropathy. J Nephrol 2000; 13: 360-6.
16. Tsuruya K, Harada A, Hirakata H, Mitsuiki K, Johko T, Kondoh H, Takechi S, Fujishima M. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy. Clin Nephrol 2000; 53: 1-9.
17. Tamura S, Ueki K, Ideura H, Tsukada Y, Maezawa A, Kawai H, Wakamatsu R, Yano S, Nojima Y, Naruse T. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 2001; 55: 192-5.
18. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, Abe K, Taguma Y. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001; 38: 736-43.
19. Pozzi C, Locatelli F. Corticosteroids in IgA nephropathy (Letter). Lancet 1999; 353: 2159-60.
20. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46.
21. McIntyre CW, Fluck RJ, Lambie SH. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: An effective treatment. Clin Nephrol 2001; 56: 193-8.
22. Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: A 3-year follow-up. Clin Nephrol 2000; 54: 360-5.
23. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-6.
24. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-24.
25. Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996; 50: 1321-6.
26. Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol 2004; 24: 218-24.
27. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-83.
28. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, Jr., Rovin BH. Renoprotection: one or many therapies? Kidney Int 2001; 59: 1211-26.
29. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: A commentary. J Am Soc Nephrol 2003; 14: 3217-32.
30. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G. Mycophenolate mofetil vs placebo in pateints at high risk for progressive IgA nephropathy: A double blind RCT (Abstract). J Am Soc Nephrol 2003; 14: 753A.
31. Hwang YC, Lee TW, Kim MJ, Yang MH, Ihm CG. Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone. Korean J Intern Med 2001; 16: 105-9.
32. Chen X, Qiu Q, Tang L, Liu S, Cai G, Liu H, Xie Y. Effects of co-administration of urokinase and benazepril on severe IgA nephropathy. Nephrol Dial Transplant 2004; 19: 852-7.
33. Dillon JJ. Fish oil therapy for IgA nephropathy: Efficacy and interstudy variability. J Am Soc Nephrol 1997; 8: 1739-44.
34. Donadio JV, Jr., Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194-9.
35. Donadio JV Jr., Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group J Am Soc Nephrol 1999; 10: 1772-7.
36. Lee GSL, Choong HL, Chiang GSC, Woo KT. Three year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology 1997; 3: 117-21.
37. Glassock RJ. The treatment of IgA nephropathy at the end of the millenium. J Nephrol 1999; 12: 288-96.
38. Floege J, Feehally J. IgA nephropathy: Recent developments. J Am Soc Nephrol 2000; 11: 2395-403.
39. Lai KN. Future directions in the treatment of IgA nephropathy. Nephron 2002; 92: 263-70.
40. Floege J, Johnson RJ. Multiple roles for platelet-derived growth factor in renal disease. Miner Electrolyte Metab 1995; 21: 271-82.
41. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic N. Novel approach to specific growth factor inhibition in vivo: Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 1999; 154: 169-79.
42. Ostendorf T, Kunter U, Groene HJ, Kawachi H, Shimizu F, Koch KM, Janjic N, Floege J. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2001; 12: 909-18.
43. Ostendorf T, van Roeyen CR, Peterson JD, Kunter U, Eitner F, Hamad AJ, Chan G, Jia XC, Macaluso J, Gazit-Bornstein G, Keyt BA, Lichenstein HS, LaRochelle WJ, Floege J. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2003; 14: 2237-47.
44. Changsirikulchai S, Hudkins KL, Goodpaster TA, Volpone J, Topouzis S, Gilbertson DG, Alpers CE. Platelet-derived growth factor-D expression in developing and mature human kidneys. Kidney Int 2002; 62: 2043-54.
45. Hudkins KL, Gilbertson DG, Carling M, Taneda S, Hughes SD, Holdren MS, Palmer TE, Topouzis S, Haran AC, Feldhaus AL, Alpers CE. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 2004; 15: 286-98.
46. Emancipator SN. Experimental models of IgA nephropathy. Am J Kidney Dis 1988; 12: 415-9.
47. Montinaro V, Gesualdo L, Schena FP. The relevance of experimental models in the pathogenetic investigation of primary IgA nephropathy. Ann Med Interne (Paris) 1999; 150: 99-107.
48. Burg M, Grone HJ, Koch KM, Floege J. Cationic dextran induces mesangioproliferative nephritis in rats independent of glomerular IgA deposition. Nephrol Dial Transplant 1997; 12: 1856-62.
49. Coppo R, Chiesa M, Cirina P, Peruzzi L, Amore A. In human IgA nephropathy uteroglobin does not play the role inferred from transgenic mice. Am J Kidney Dis 2002; 40: 495-503.
50. Williams DG. Pathogenesis of idiopathic IgA nephropathy. Pediatr Nephrol 1993; 7: 303-11.
51. Endo Y. IgA nephropathy-human disease and animal model. Ren Fail 1997; 19: 347-71.
52. Eitner F, Ostendorf T, Kitahara M, Floege J. A novel model of human IgA nephropathy (Abstract). J Am Soc Nephrol 2001; 12: 675A.
53. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: A repeat biopsy study. Am J Kidney Dis 2002; 39: 493-502.
54. Kawasaki Y, Suzuki J, Sakai N, Etoh S, Murai H, Nozawa R, Suzuki H. Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy. Am J Nephrol 2004; 24: 147-53.
55. Rasche FM, Klotz CH, Czock D, Karges W, Muche R, Jehle PM, Mertz A, Keller F. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clin Pract 2003; 93: c131-6.
56. Carruthers SG, Larochelle P, Haynes RB, Petrasovits A, Schiffrin EL. Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. Cmaj 1993; 149: 289-93.